Cargando…

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in BRAF, NRAS, or NF1 form 10% of human melanomas and are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krebs, Fanny Seraphine, Moura, Bianca, Missiaglia, Edoardo, Aedo-Lopez, Veronica, Michielin, Olivier, Tsantoulis, Petros, Bisig, Bettina, Trimech, Mounir, Zoete, Vincent, Homicsko, Krisztian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003177/ https://www.ncbi.nlm.nih.gov/pubmed/36901951 http://dx.doi.org/10.3390/ijms24054520

Ejemplares similares

Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
por: Krebs, Fanny S., et al.
Publicado: (2020)

Structure-based prediction of BRAF mutation classes using machine-learning approaches
por: Krebs, Fanny S., et al.
Publicado: (2022)

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient
por: Anchisi, Sandro, et al.
Publicado: (2023)

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma
por: Aedo-Lopez, Veronica, et al.
Publicado: (2022)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss
por: Frisone, Daniele, et al.
Publicado: (2019)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology
por: Krebs, Fanny S., et al.
Publicado: (2021)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations
por: Roberti, Annalisa, et al.
Publicado: (2016)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
por: Bangi, Erdem, et al.
Publicado: (2019)

Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines
por: Appleton, Kathryn M., et al.
Publicado: (2021)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma
por: Crippa, Stefania, et al.
Publicado: (2017)

SwissDock, a protein-small molecule docking web service based on EADock DSS
por: Grosdidier, Aurélien, et al.
Publicado: (2011)

Docking, virtual high throughput screening and in silico fragment-based drug design
por: Zoete, Vincent, et al.
Publicado: (2009)

SwissSidechain: a molecular and structural database of non-natural sidechains
por: Gfeller, David, et al.
Publicado: (2013)

T-Cell Receptors Binding Orientation over Peptide/MHC Class I Is Driven by Long-Range Interactions
por: Ferber, Mathias, et al.
Publicado: (2012)

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
por: Daina, Antoine, et al.
Publicado: (2017)

SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules
por: Daina, Antoine, et al.
Publicado: (2019)

Trametinib: A Targeted Therapy in Metastatic Melanoma
por: Hoffner, Brianna, et al.
Publicado: (2018)

Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021)

Standards of care and novel approaches in the management of glioblastoma multiforme
por: Hottinger, Andreas F., et al.
Publicado: (2014)

Lymph node involvement by enteropathy-like indolent NK-cell proliferation
por: Dargent, Jean-Louis, et al.
Publicado: (2020)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2021)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Rapamycin and trametinib: a rational combination for treatment of NSCLC
por: Sun, Chao-Yue, et al.
Publicado: (2021)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8fufkie18hklra2r22tas79k9